BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 30053001)

  • 1. Feminizing Adrenocortical Carcinoma: The Source of Estrogen Production and the Role of Adrenal-Gonadal Dedifferentiation.
    Wu L; Xie J; Jiang L; Su T; Ye L; Zhou W; Jiang Y; Zhang C; Ning G; Wang W
    J Clin Endocrinol Metab; 2018 Oct; 103(10):3706-3713. PubMed ID: 30053001
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of the Tcf/beta-catenin complex increases apoptosis and impairs adrenocortical tumor cell proliferation and adrenal steroidogenesis.
    Leal LF; Bueno AC; Gomes DC; Abduch R; de Castro M; Antonini SR
    Oncotarget; 2015 Dec; 6(40):43016-32. PubMed ID: 26515592
    [TBL] [Abstract][Full Text] [Related]  

  • 3. BCL9 Upregulation in Adrenocortical Carcinoma: A Novel Wnt/β-Catenin Activating Event Driving Adrenocortical Malignancy.
    Brown TC; Nicolson NG; Korah R; Carling T
    J Am Coll Surg; 2018 Jun; 226(6):988-995. PubMed ID: 29428231
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Investigation of N-cadherin/β-catenin expression in adrenocortical tumors.
    Rubin B; Regazzo D; Redaelli M; Mucignat C; Citton M; Iacobone M; Scaroni C; Betterle C; Mantero F; Fassina A; Pezzani R; Boscaro M
    Tumour Biol; 2016 Oct; 37(10):13545-13555. PubMed ID: 27468715
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rottlerin as a novel chemotherapy agent for adrenocortical carcinoma.
    Zhu Y; Wang M; Zhao X; Zhang L; Wu Y; Wang B; Hu W
    Oncotarget; 2017 Apr; 8(14):22825-22834. PubMed ID: 28423559
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Steroid metabolites for diagnosing and predicting clinicopathological features in cortisol-producing adrenocortical carcinoma.
    Suzuki S; Minamidate T; Shiga A; Ruike Y; Ishiwata K; Naito K; Ishida A; Deguchi H; Fujimoto M; Koide H; Tatsuno I; Ikeda JI; Yamazaki Y; Sasano H; Yokote K
    BMC Endocr Disord; 2020 Nov; 20(1):173. PubMed ID: 33228607
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Livin/BIRC7 expression as malignancy marker in adrenocortical tumors.
    Altieri B; Sbiera S; Della Casa S; Weigand I; Wild V; Steinhauer S; Fadda G; Kocot A; Bekteshi M; Mambretti EM; Rosenwald A; Pontecorvi A; Fassnacht M; Ronchi CL
    Oncotarget; 2017 Feb; 8(6):9323-9338. PubMed ID: 28030838
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adrenocortical carcinoma: review of the pathologic features, production of adrenal steroids, and molecular pathogenesis.
    Nakamura Y; Yamazaki Y; Felizola SJ; Ise K; Morimoto R; Satoh F; Arai Y; Sasano H
    Endocrinol Metab Clin North Am; 2015 Jun; 44(2):399-410. PubMed ID: 26038208
    [TBL] [Abstract][Full Text] [Related]  

  • 9. STMN1 is Overexpressed in Adrenocortical Carcinoma and Promotes a More Aggressive Phenotype In Vitro.
    Aronova A; Min IM; Crowley MJP; Panjwani SJ; Finnerty BM; Scognamiglio T; Liu YF; Whitsett TG; Garg S; Demeure MJ; Elemento O; Zarnegar R; Fahey TJ
    Ann Surg Oncol; 2018 Mar; 25(3):792-800. PubMed ID: 29214451
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Feminizing adrenocortical carcinoma with selective suppression of follicle-stimulating hormone secretion and disorganized steroidogenesis: a case report and literature review.
    Saito T; Tojo K; Furuta N; Ono K; Sasano H; Utsunomiya K
    Intern Med; 2011; 50(13):1419-24. PubMed ID: 21720063
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Silencing of MED27 inhibits adrenal cortical carcinogenesis by targeting the Wnt/β-catenin signaling pathway and the epithelial-mesenchymal transition process.
    He H; Dai J; Yang X; Wang X; Sun F; Zhu Y
    Biol Chem; 2018 May; 399(6):593-602. PubMed ID: 29730647
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterization of differential gene expression in adrenocortical tumors harboring beta-catenin (CTNNB1) mutations.
    Durand J; Lampron A; Mazzuco TL; Chapman A; Bourdeau I
    J Clin Endocrinol Metab; 2011 Jul; 96(7):E1206-11. PubMed ID: 21565795
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A case of estrogen-secreting adrenocortical carcinoma with subclinical Cushing's syndrome.
    Fukai N; Hirono Y; Yoshimoto T; Doi M; Ohtsuka Y; Homma K; Shibata H; Sasano H; Hirata Y
    Endocr J; 2006 Apr; 53(2):237-45. PubMed ID: 16618983
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Survivin in adrenocortical tumors - pathophysiological implications and therapeutic potential.
    Sbiera S; Kroiss M; Thamm T; Beyer M; Majidi F; Kuehner D; Wobser M; Becker JC; Adam P; Ronchi C; Allolio B; Fassnacht M
    Horm Metab Res; 2013 Feb; 45(2):137-46. PubMed ID: 23143666
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cytotoxic Effect of Progesterone, Tamoxifen and Their Combination in Experimental Cell Models of Human Adrenocortical Cancer.
    Rossini E; Tamburello M; Abate A; Beretta S; Fragni M; Cominelli M; Cosentini D; Hantel C; Bono F; Grisanti S; Poliani PL; Tiberio GAM; Memo M; Sigala S; Berruti A
    Front Endocrinol (Lausanne); 2021; 12():669426. PubMed ID: 33981288
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antisecretive and Antitumor Activity of Abiraterone Acetate in Human Adrenocortical Cancer: A Preclinical Study.
    Fiorentini C; Fragni M; Perego P; Vezzoli S; Bonini SA; Tortoreto M; Galli D; Claps M; Tiberio GA; Terzolo M; Missale C; Memo M; Procopio G; Zaffaroni N; Berruti A; Sigala S
    J Clin Endocrinol Metab; 2016 Dec; 101(12):4594-4602. PubMed ID: 27626976
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interferon-β is a potent inhibitor of cell growth and cortisol production in vitro and sensitizes human adrenocortical carcinoma cells to mitotane.
    van Koetsveld PM; Vitale G; Feelders RA; Waaijers M; Sprij-Mooij DM; de Krijger RR; Speel EJ; Hofland J; Lamberts SW; de Herder WW; Hofland LJ
    Endocr Relat Cancer; 2013 Jun; 20(3):443-54. PubMed ID: 23507702
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adrenocortical stem and progenitor cells: implications for adrenocortical carcinoma.
    Simon DP; Hammer GD
    Mol Cell Endocrinol; 2012 Mar; 351(1):2-11. PubMed ID: 22266195
    [TBL] [Abstract][Full Text] [Related]  

  • 19. IGF2 role in adrenocortical carcinoma biology.
    Pereira SS; Monteiro MP; Costa MM; Moreira Â; Alves MG; Oliveira PF; Jarak I; Pignatelli D
    Endocrine; 2019 Nov; 66(2):326-337. PubMed ID: 31378849
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A novel FOXO1-mediated dedifferentiation blocking role for DKK3 in adrenocortical carcinogenesis.
    Cheng JY; Brown TC; Murtha TD; Stenman A; Juhlin CC; Larsson C; Healy JM; Prasad ML; Knoefel WT; Krieg A; Scholl UI; Korah R; Carling T
    BMC Cancer; 2017 Mar; 17(1):164. PubMed ID: 28249601
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.